loader2
NRI

Innova Captab Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
Incur '0' Brokerage upto ₹500
Innova Captab Ltd. 11 Aug 2024 22:18 PM

Q1FY25 Quarterly Result Announced for Innova Captab Ltd.

Pharmaceuticals company Innova Captab announced Q1FY25 results: 

  • Revenue from operation is Rs 294.3 crore in Q1FY25 as against Rs 233.2 crore of Q1FY24 registering a growth of 26%.
  • The Company’s EBITDA stood at Rs 44.3 crore in Q1FY25 against Rs 32.4 crore of Q1FY24 registering a growth of 37%.
  • Profit After Tax (PAT) stood at Rs 29.5 crore in Q1FY25 against Rs 17.6 crore of Q1FY24 registering a growth of 68%

Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab said, For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters.

Over the past 3-4 years, our revenue has grown at a robust growth rate. With the new Jammu facility, we are optimistic about sustaining this growth trajectory over the next few years.

As a company, we remain committed to driving sustainable growth by exploring new opportunities and focusing on value-added products. The Indian pharmaceutical sector is poised for significant growth in the mid to long term, with both domestic and global MNCs are increasingly seeking reliable and sustainable suppliers like us.

The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India’s top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities.

By Q2FY25, the upcoming greenfield plant in Jammu is expected to be commercialized. This facility will have four production blocks: cephalosporin, penicillin, penum and BFS and will manufacture oral solid dosages, dry powder injections, dry syrup, BFS, Large Volume Parenterals and respiratory respule products.

Result PDF

Pharmaceuticals company Innova Captab announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operation is Rs 262.63 crore in Q4FY24 as against Rs 240.95 crore of previous year registering a growth of 9.0%.
  • The Company’s EBITDA stood at Rs 43.76 crore in Q4FY24 against Rs 29.42 crore of previous year registering a growth of 48.7%.
  • Profit After Tax (PAT) stood at Rs 28.72 crore in Q4FY24 against Rs 17.25 crore of previous year registering a growth of 66.5%.

FY24 Financial Highlights:

  • Total Income for the FY24 stood at Rs 1,093.79 crore against Rs 935.58 crore in FY23 with growth of 16.9% over FY23.
  • Revenue from Operation has increased to Rs 1,081.31 crore in FY24 from Rs 926.38 crore in FY23, registering a growth of 16.7%.
  • The Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) stands at Rs 166.94 crore in FY24, as against Rs 122.85 crore in FY23, with an increase of 35.9%.
  • Profit After Tax (PAT) is Rs 94.35 crore in FY24 as against Rs 67.95 crore in FY23, registering a growth of 38.9%.
  • Earnings per share (EPS) for FY24 is Rs 18.66, against Rs 14.16 in FY23
  • For FY24, net cash generated from operating activities stood at Rs 146 crore, against Rs 67 crore in FY23.

Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab Limited said, For FY24, we reported a total income of Rs 1,094 crore with a growth of 16.9% compared to the previous year. Our all business areas are getting good traction and are expected to grow at a healthy rate in the coming years.

Over the last 3-4 years, we have grown at a healthy rate of ~ 20% CAGR. With our upcoming Jammu facility and recent Sharon acquisition, we are positively looking forward to maintaining the same healthy growth rate over the next 3-4 years.

As a company we continue to drive sustainable growth by exploring new opportunities and focusing on value-added products. Indian pharmaceutical companies are set to experience significant growth in the mid to long term, as both domestic and global manufacturers seek reliable and sustainable suppliers like us.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app